MorningMed is a community of 814,300 medical professionals

We're a place where medical professionals share news and other news items to help their peers stay up to date

All articles tagged: Malignant neoplasm of ovary (C56)

HealthDay 11 July at 04.04 PM

GLP-1 RAs May Reduce Risk for Some Obesity-Linked Cancers Versus Insulin in T2D

For patients with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for 10 of 13 obesity-associated cancers (OACs) compared with insulin, according to a study published online July 5 in JAMA Network Open.Lindsey Wang, from Case Western Reserve University School of Medicine

HealthDay 13 June at 11.17 AM

J&J Settles Talcum Powder Lawsuits From States for $700 Million

Johnson & Johnson will pay $700 million to settle claims from 42 states and the District of Columbia that the company continued to market its talcum powder products even as evidence tied them to a heightened risk for cancer.J&J did not admit to any wrongdoing in settling with the states, which were led by Florida, Texas and North Carol

Evalytics 01 April at 06.18 PM

Princess Kate is undergoing 'preventative chemotherapy.' What does that mean?

Princess Kate Middleton's decision for risk-reducing surgery to prevent ovarian cancer has sparked discussions about genetic testing and cancer prevention. This highlights the importance of genetic counseling and testing for those with a family history of cancer to assess and mitigate their risk.

HealthDay 12 December at 04.14 PM

White Women Overrepresented in Gynecologic Cancer Trials

White women are disproportionately represented in clinical trials for gynecologic cancers, according to a study published online Dec. 7 in JAMA Network Open.Wafa Khadraoui, M.D., from The Ohio State University in Columbus, and colleagues examined the association of race and ethnicity with clinical trial enrollment among women with

HealthDay 07 December at 04.50 PM

Mirvetuximab Soravtansine-Gynx Beneficial for FRα-Positive Ovarian Cancer

For patients with high folate receptor α (FRα)-positive ovarian cancer, a first-in-class antibody-drug conjugate targeting FRα, mirvetuximab soravtansine-gynx (MIRV), shows a significant benefit over chemotherapy, according to a study published in the Dec. 7 issue of the New England Journal of Medicine.Kathleen N. Moore, M.D., from the